Cognitive status correlates with neuropathologic stage in Parkinson disease
Abstract
Objective: To study the association of cognitive status with the stages of a published neuropathologic staging procedure for sporadic Parkinson disease (PD) in a cohort of 88 patients with PD from a single neurologic unit. None had received the clinical diagnosis of dementia with Lewy bodies (DLB).
Methods: The authors assessed Lewy neurites/bodies (LNs/LBs) immunoreactive for α-synuclein semiquantitatively in sections from 18 brain regions. In silver-stained sections and sections immunostained for tau and β-amyloid protein, the authors semiquantitatively evaluated comorbidities potentially contributing to cognitive decline, e.g., Alzheimer disease (AD), argyrophilic grain disease (AGD), and cerebral vascular disease. The authors analyzed four Mini-Mental State Examination (MMSE) subgroups ranging from marginally impaired cognition to severe dementia using nonparametric tests.
Results: It was possible to assign all patients to one of the PD stages. MMSE scores correlated with neuropathologic stages (p < 0.005) and this association showed a linear trend (p < 0.025). Median MMSE test scores for women were lower than those for men. Cognitively impaired individuals displayed higher stages of AD-related neurofibrillary pathology (p < 0.05) and β-amyloid deposition (p < 0.05) than cognitively unimpaired persons. MMSE scores did not correlate significantly with AGD, disease duration, age at disease onset, or age at death. Hoehn and Yahr scores, however, correlated with PD stages (p < 0.0005) and MMSE scores (p < 0.0005).
Conclusions: The decrease in median Mini-Mental State Examination scores between PD stages 3 to 6 indicates that the risk of developing dementia increases with disease progression. In some individuals, however, cognitive decline can develop in the presence of mild Parkinson disease–related cortical pathology and, conversely, widespread cortical lesions do not necessarily lead to cognitive decline.
Get full access to this article
View all available purchase options and get full access to this article.
Supplementary Material
References
1.
Hansen LA, Galasko D. Lewy body disease. Curr Opinion Neurol Neurosurg 1992;5:889–894.
2.
McKeith IG, Perry EK, Perry RH. Report of the second dementia with Lewy body international workshop: diagnosis and treatment. Consortium on dementia with Lewy bodies. Neurology 1999;53:902–905.
3.
Cummings J. Reconsidering diagnostic criteria for dementia with Lewy bodies: highlights from the Third International Workshop on Dementia with Lewy Bodies and Parkinson’s Disease Dementia, September 17–20, 2003, Newcastle upon Tyne, United Kingdom. Rev Neurol Dis 2004;1:31–34.
4.
Pollanen MS, Dickson DW, Bergeron C. Pathology and biology of the Lewy body. J Neuropathol Exp Neurol 1993;52:183–191.
5.
Braak H, Braak E, Yilmazer D, et al. Amygdala pathology in Parkinson’s disease. Acta Neuropathol 1994;88:493–500.
6.
Braak H, de Vos RAI, Jansen ENH, Bratzke HJ, Braak E. Neuropathological hallmarks of Alzheimer’s and Parkinson’s diseases. Progr Brain Res 1998;117:267–285.
7.
Apaydin H, Ahlskog E, Parisi JE, Boeve BF, Dickson DW. Parkinson disease neuropathology: late-developing dementia and loss of the levodopa response. Arch Neurol 2002;59:102–112.
8.
Golbe LI. Alpha-synuclein and Parkinson’s disease. Mov Disord 1999;14:6–9.
9.
Cole NB, Murphy DD. The cell-biology of alpha-synuclein: a sticky problem? Neuromol Med 2002;1:95–109.
10.
Gomez-Tortosa E, Ingraham AO, Irizarry MC, Hyman BT. Dementia with Lewy bodies. J Am Geriatr Soc 1998;46:1449–1458.
11.
Gomez-Tortosa E, Newell K, Irizarry MC, Albert M, Growdon JH, Hyman BT. Clinical and quantitative pathologic correlates of dementia with Lewy bodies. Neurology 1999;53:1284–1291.
12.
Kosaka K. Diffuse Lewy body disease. Neuropathology 2000;20(suppl):73–78.
13.
Marui W, Iseki E, Nakai T, et al. Progression and staging of Lewy pathology in brains from patients with dementia with Lewy bodies. J Neurol Sci 2002;195:153–159.
14.
Uchikado H, Iseki E, Tsuchiya K, et al. Dementia with Lewy bodies showing advanced Lewy pathology but minimal Alzheimer pathology—Lewy pathology causes neuronal loss inducing progressive dementia. Clin Neuropathol 2002;21:269–277.
15.
Harding AJ, Halliday GM. Cortical Lewy body pathology in the diagnosis of dementia. Acta Neuropathol 2001;102:355–363.
16.
Foltynie T, Brayne C, Barker RA. The heterogeneity of idiopathic Parkinson’s disease. J Neurol 2002;249:138–145.
17.
Hegeman Richard I, Papka M, Rubio A, Kurlan R. Parkinson’s disease and dementia with Lewy bodies: one disease or two? Mov Disord 2002;17:1161–1165.
18.
Colosimo C, Hughes AJ, Kilford L, Lees AJ. Lewy body cortical involvement may not always predict dementia in Parkinson’s disease. J Neurol Neurosurg Psychiatry 2003;74:852–856.
19.
Braak H, Del Tredici K, Rüb U, de Vos RAI, Jansen Steur ENH, Braak E. Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging 2003;24:197–210.
20.
Saito Y, Ruberu NY, Sawabe M, et al. Lewy body-related α-synucleinopathy in aging. J Neuropathol Exp Neurol 2004;63:742–749.
21.
Wolters EC, Francot C, Bergmans P, et al. Preclinical (premotor) Parkinson’s disease. J Neurol 2000;247(suppl 2):103–109.
22.
Del Tredici K, Rüb U, de Vos RAI, Bohl JRE, Braak H. Where does Parkinson disease pathology begin in the brain? J Neuropathol Exp Neurol 2002;61:413–426.
23.
Del Tredici K, Braak H. Idiopathic Parkinson’s disease: staging an α-synucleinopathy with a predictable pathoanatomy. In: Kahle P, Haass C, eds. Molecular mechanisms in Parkinson’s disease. Georgetown, TX: Landes Bioscience, 2004;1–32.
24.
Mayeux R, Denaro J, Hemenegildo N, et al. A population-based investigation of Parkinson’s disease with and without dementia: relationship to age and gender. Arch Neurol 1992;49:492–497.
25.
Dubois B, Pillon B. Cognitive deficits in Parkinson’s disease. J Neurol 1997;244:2–8.
26.
Hughes TA, Ross HF, Musa S, et al. A 10-year study of the incidence of and factors predicting dementia in Parkinson’s disease. Neurology 2000;54:1596–1602.
27.
Aarsland D, Andersen K, Larsen JP, Lolk A, Kragh-Sorensen P. Prevalence and characteristics of dementia in Parkinson disease. An 8-year prospective study. Arch Neurol 2003;60:387–392.
28.
Emre M. What causes mental dysfunction in Parkinson’s disease. Mov Disord 2003;18(suppl 6):S63–71.
29.
McKeith IG, Mosimann UP. Dementia with Lewy bodies and Parkinson’s disease. Parkinsonism Relat Disord 2004;10(suppl 1):S15–18.
30.
Ball MJ. The morphological basis of dementia in Parkinson’s disease. Can J Neurol Sci 1984;11(suppl 1):180–184.
31.
Mattila PM, Röyttä M, Torikka H, Dickson DW, Rinne JO. Cortical Lewy bodies and Alzheimer-type changes in patients with Parkinson’s disease. Acta Neuropathol 1998;95:576–582.
32.
Kotzbauer PT, Trojanowski JQ, Lee VM. Lewy body pathology in Alzheimer’s disease. J Mol Neurosci 2001;17:225–232.
33.
Jellinger KA, Seppi K, Wenning GK, Poewe W. Impact of coexistent Alzheimer pathology on the natural history of Parkinson’s disease. J Neural Transm 2002;109:329–339.
34.
Jendroska K, Lees AJ, Poewe W, Daniel SE. Amyloid beta-peptide and the dementia of Parkinson’s disease. Mov Disord 1996;11:647–653.
35.
Braak H, Braak E. Cortical and subcortical argyrophilic grains characterize a disease associated with adult onset dementia. Neuropathol Appl Neurobiol 1989;15:13–26.
36.
Iseki E, Togo T, Suzuki K, et al. Dementia with Lewy bodies from the perspective of tauopathy. Acta Neuropathol 2003;105:265–270.
37.
Morris JC. The clinical dementia rating (CDR): current version and scoring rules. Neurology 1993;43:2412–2414.
38.
Morris JC, Storandt M, Miller JP, et al. Mild cognitive impairment represents early-stage Alzheimer’s disease. Arch Neurol 2001;58:397–405.
39.
Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992;55:181–184.
40.
Gelb DJ, Oliver E, Gilman S. Diagnostic criteria for Parkinson’s disease. Arch Neurol 1999;56:33–39.
41.
Goetz CG, Poewe W, Rascol O, et al. Movement Disorder Society Task Force report on the Hoehn and Yahr staging scale: status and recommendations. Mov Disord 2004;19:1020–1028.
42.
American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 4th edition. Washington, DC: American Psychiatric Association, 1999.
43.
Folstein MF, Folstein SE, McHugh PR. “Mini-mental state.” A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189–198.
44.
Vertesi A, Lever JA, Molloy DW, et al. Standardized Mini-Mental State Examination. Use and interpretation. Can Fam Physician 2001;47:2018–2023.
45.
Knopman DS, Boeve BF, Petersen RC. Essentials of the proper diagnoses of mild cognitive impairment, dementia, and major subtypes of dementia. Mayo Clin Proc 2003;78:1290–1308.
46.
Gibb WR. Research diagnostic criteria for Parkinson’s disease. Adv Neurol 1990;53:245–249.
47.
Schneider JA, Wilson RS, Cochran EJ, et al. Relation of cerebral infarctions to dementia and cognitive function in older persons. Neurology 2003;60:1082–1088.
48.
Thal DR, Del Tredici K, Braak H. Neurodegeneration in normal brain aging and disease. Sci Aging Knowledge Environ 2004;23:pe26.
49.
Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 1991;82:239–259.
50.
Revesz T, Ghiso J, Lashley T, et al. Cerebral amyloid angiopathies: a pathologic, biochemical, and genetic view. J Neuropathol Exp Neurol 2003;62:885–898.
51.
Jellinger KA. Dementia with grains (argyrophilic grain disease). Brain Pathol 1998;8:377–386.
52.
Gomez-Tortosa E, Newell K, Irizarry MC, Albert M, Growdon JH, Hyman BT. α-Synuclein immunoreactivity in dementia with Lewy bodies: morphological staging and comparison with ubiquitin immunostaining. Acta Neuropathol 2000;99:352–357.
53.
Lennox G, Lowe J, Landon M, Byrne EJ, Mayer RJ, Godwin-Austen RB. Diffuse Lewy body disease: correlative neuropathology using anti-ubiquitin immunocytochemistry. J Neurol Neurosurg Psychiatry 1989;52:1236–1247.
54.
Braak H, Braak E. Demonstration of amyloid deposits and neurofibrillary changes in whole brain sections. Brain Pathol 1991;1:213–216.
55.
Jellinger K. Alpha-synuclein pathology in Parkinson’s and Alzheimer’s disease brain: incidence and topographic distribution—a pilot study. Acta Neuropathol 2003;106:191–201.
56.
Iseki E, Marui W, Kosaka K, Uéda K. Frequent coexistence of Lewy bodies and neurofibrillary tangles in the same neurons of patients with diffuse Lewy body disease. Neurosci Lett 1999;265:9–12.
57.
Davis DG, Schmitt FA, Wekstein DR, Markesbery WR. Alzheimer neuropathologic alteration in aged cognitively normal subjects. J Neuropathol Exp Neurol 1999;58:376–388.
58.
Grober E, Dickson D, Sliwinski MJ, et al. Memory and mental status correlates of modified Braak staging. Neurobiol Aging 1999;20:573–579.
59.
Gold G, Bouras C, Kövari E, et al. Clinical validity of Braak neuropathological staging in the oldest old. Acta Neuropathol 2000;99:579–582.
60.
Riley KP, Snowdon DA, Markesbery WR. Alzheimer’s neurofibrillary pathology and the spectrum of cognitive function: findings from the nun study. Ann Neurol 2002;51:567–577.
61.
Salganik I, Korczyn A. Risk factors for dementia in Parkinson’s disease. In: Streifler MB, Korczyn AD, Melamed E, Youdin MBH, eds. Parkinson’s disease: anatomy, pathology, and therapy. Advances in neurology 53. New York: Raven Press, 1990;343–347.
62.
Petersen RC, Doody R, Kurz A, et al. Current concepts in mild cognitive impairment. Arch Neurol 2001;58:1985–1992.
63.
Inzelberg R, Plotnik M, Flash T, Schechtman E, Shahar I, Korczyn AD. Switching abilities in Parkinson’s disease. Adv Neurol 1996;69:361–369.
64.
Marinus J, Visser M, Verwey NA, et al. Assessment of cognition in Parkinson’s disease. Neurology 2003;61:1222–1228.
65.
Tang-Wai DF, Knopman DS, Yonas E, et al. Comparison of the short test of mental status and the Mini-Mental State Examination in mild cognitive impairment. Arch Neurol 2003;60:1777–1781.
66.
Noe E, Marder K, Bell KL, Jacobs DM, Manly JJ, Stern Y. Comparison of dementia with Lewy bodies to Alzheimer’s disease and Parkinson’s disease with dementia. Mov Disord 2004;19:60–67.
67.
Hughes AJ, Daniel SE, Blankson S, Lees AJ. A clinicopathologic study of 100 cases of Parkinson’s disease. Arch Neurol 1993;50:140–148.
68.
Lowe J, Dickson D. Pathological diagnostic criteria for dementia associated with cortical Lewy bodies: review and proposal for a descriptive approach. J Neural Transm 1997;51(suppl):111–120.
69.
Xuereb JH, Tomlinson BE, Irving D, Perry RH, Blessed G, Perry EK. Cortical and subcortical pathology in Parkinson’s disease: relationship to parkinsonian dementia. Adv Neurol 1990;53:35–40.
70.
Saper CB, Sorrentino DM, German DC, de Lacalle S. Medullary catecholaminergic neurons in the normal human brain and in Parkinson’s disease. Ann Neurol 1991;29:577–584.
71.
Zweig RM, Cardillo JE, Cohen M, Giere S, Hedreen JC. The locus ceruleus and dementia in Parkinson’s disease. Neurology 1993;43:986–991.
72.
Rinne JO, Rummukainen J, Paljarvi L, Rinne UK. Dementia in Parkinson’s disease is related to neuronal loss in the medial substantia nigra. Ann Neurol 1989;26:47–50.
73.
Whitehouse PJ, Hedreen JC, White CL, Price DL. Basal forebrain neurons in the dementia of Parkinson’s disease. Ann Neurol 1983;13:243–248.
74.
Duyckaerts C, Gaspar P, Costa C, Bonnet AM, Hauw JJ. Dementia in Parkinson’s disease: morphometric data. Adv Neurol 1993;60:447–455.
75.
Rüb U, Del Tredici K, Schultz C, et al. Parkinson’s disease: the thalamic components of the limbic loop are severely impaired by α-synuclein immunopositive inclusion body pathology. Neurobiol Aging 2002;23:245–254.
76.
Parent A, Hazrati LN. Functional anatomy of the basal ganglia. I. The cortico-basal-ganglia-thalamo-cortico-loop. Brain Res Rev 1995;20:91–127.
77.
Heimer L, de Olmos J, Alheid GF, Zaborszky L. “Perestroika” in the basal forebrain: opening the border between neurology and psychiatry. Progr Brain Res 1991;87:109–165.
78.
Woods SP, Tröster AI. Prodromal frontal/executive dysfunction predicts incident dementia in Parkinson’s disease. J Int Neuropsychol Soc 2003;9:17–24.
79.
Kövari E, Gold G, Herrmann FR, et al. Lewy body densities in the entorhinal and anterior cingulate cortex predict cognitive deficits in Parkinson’s disease. Acta Neuropathol 2003;106:83–88.
80.
Sugiyama H, Hainfellner JA, Yoshimura M, Budka H. Neocortical changes in Parkinson’s disease, revisited. Clin Neuropathol 1994;13:55–59.
81.
Mattila PM, Rinne JO, Helenius H, Dickson DW, Röyttä M. Alpha-synuclein-immunoreactive cortical Lewy bodies are associated with cognitive impairment in Parkinson’s disease. Acta Neuropathol 2000;100:285–290.
82.
Hurtig HI, Trojanowski JQ, Galvin J, et al. Alpha-synuclein cortical Lewy bodies correlate with dementia in Parkinson’s disease. Neurology 2000;54:1916–1921.
83.
Samuel W, Galasko D, Masliah E, Hansen LA. Neocortical Lewy body counts correlate with dementia in the Lewy body variant of Alzheimer’s disease. J Neuropathol Exp Neurol 1996;55:44–52.
84.
Perry RH, Irving D, Blessed G, Fairbairn A, Perry EK. Senile dementia of Lewy body type. A clinically and neuropathologically distinct form of Lewy body dementia in the elderly. J Neurol Sci 1990;95:119–139.
85.
Gómez-Isla T, Growdon WB, McNamara M, et al. Clinicopathologic correlates in temporal cortex in dementia with Lewy bodies. Neurology 1999;53:2003–2009.
86.
de Vos RAI, Jansen ENH, Stam FC, Ravid R, Swaab D. Lewy body disease: clinico-pathological correlations in 18 consecutive cases of Parkinson’s disease with and without dementia. Clin Neurol Neurosurg 1995;97:13–22.
87.
Wakabayashi K, Hansen LA, Masliah E. Cortical Lewy body-containing neurons are pyramidal cells. Laser confocal imaging of double-immunolabeled sections with anti-ubiquitin and SMI32. Acta Neuropathol 1995;89:404–408.
88.
Dickson DW, Schmidt ML, Lee VMY, Zhao ML, Yen SH, Trojanowski JQ. Immunoreactivity profile of hippocampal CA2/3 neurites in diffuse Lewy body disease. Acta Neuropathol 1994;87:269–276.
89.
Lee VM-Y, Trojanowski JQ. Research on the brain. Sci Aging Knowledge Environ 2003;42:pe29.
90.
Jellinger KA. Morphological substrates of mental dysfunction in Lewy body disease: an update. J Neural Transm 2000;59(suppl):185–212.
91.
Schmidt ML, Martin JA, Lee VMY, Trojanowski JQ. Convergence of Lewy bodies and neurofibrillary tangles in amygdala neurons of Alzheimer’s disease and Lewy bodies disorders. Acta Neuropathol 1996;91:475–481.
92.
Marui W, Iseki E, Uéda K, Kosaka K. Occurrence of human α-synuclein immunoreactive neurons with neurofibrillary tangle formation in the limbic areas of patients with Alzheimer’s disease. J Neurol Sci 2000;174:81–84.
93.
Ishizawa T, Mattila P, Davies P, Wang D, Dickson DW. Colocalization of tau and alpha-synuclein epitopes in Lewy bodies. J Neuropathol Exp Neurol 2003;62:389–397.
94.
Braak H, Braak E, Yilmazer E, de Vos RA, Jansen EN, Bohl J. Pattern of brain destruction in Parkinson’s and Alzheimer’s diseases. J Neural Transm 1996;103:455–490.
Information & Authors
Information
Published In
Copyright
© 2005.
Publication History
Published online: April 25, 2005
Published in print: April 26, 2005
Authors
Metrics & Citations
Metrics
Citation information is sourced from Crossref Cited-by service.
Citations
Download Citations
If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Select your manager software from the list below and click Download.
Cited By
- Cardiovascular dysautonomia and cognitive impairment in Parkinson's disease (Review), Medicine International, 4, 6, (2024).https://doi.org/10.3892/mi.2024.194
- From Synaptic Physiology to Synaptic Pathology: The Enigma of α-Synuclein, International Journal of Molecular Sciences, 25, 2, (986), (2024).https://doi.org/10.3390/ijms25020986
- Clinical and cognitive features associated with psychosis in Parkinson's disease: a longitudinal study, Frontiers in Aging Neuroscience, 16, (2024).https://doi.org/10.3389/fnagi.2024.1463426
- Primary cilia in Parkinson’s disease: summative roles in signaling pathways, genes, defective mitochondrial function, and substantia nigra dopaminergic neurons, Frontiers in Aging Neuroscience, 16, (2024).https://doi.org/10.3389/fnagi.2024.1451655
- α-Synuclein: Multiple pathogenic roles in trafficking and proteostasis pathways in Parkinson’s disease, The Neuroscientist, 30, 5, (612-635), (2024).https://doi.org/10.1177/10738584241232963
- Brain Connectivity Networks Constructed Using MRI for Predicting Patterns of Atrophy Progression in Parkinson Disease, Radiology, 311, 3, (2024).https://doi.org/10.1148/radiol.232454
- Effects of a Concurrent Working Memory Task on Speech Acoustics in Parkinson's Disease, American Journal of Speech-Language Pathology, 33, 1, (418-434), (2024).https://doi.org/10.1044/2023_AJSLP-23-00214
- Parkinson's disease progression is multifaceted: Evidence for the underlying benchmarks, Parkinsonism & Related Disorders, 121, (106037), (2024).https://doi.org/10.1016/j.parkreldis.2024.106037
- Region-specific changes in gene expression are associated with cognitive deficits in the alpha-synuclein-induced model of Parkinson's disease: A transcriptomic profiling study, Experimental Neurology, 372, (114651), (2024).https://doi.org/10.1016/j.expneurol.2023.114651
- Neuropsychologie du vieillissement normal et des syndromes démentiels, Neuropsychologie, (532-692), (2024).https://doi.org/10.1016/B978-2-294-78570-2.00023-X
- See more
Loading...
View Options
Login options
Check if you have access through your login credentials or your institution to get full access on this article.
Personal login Institutional LoginPurchase Options
The neurology.org payment platform is currently offline. Our technical team is working as quickly as possible to restore service.
If you need immediate support or to place an order, please call or email customer service:
- 1-800-638-3030 for U.S. customers - 8:30 - 7 pm ET (M-F)
- 1-301-223-2300 for customers outside the U.S. - 8:30 - 7 pm ET (M-F)
- [email protected]
We appreciate your patience during this time and apologize for any inconvenience.